"A novel non-invasive cardiac imaging technology is required to further unravel and characterize the disease processes associated with atherosclerosis, in particular those associated with vulnerable plaque formation which is a major risk factor for stroke and heart attacks," says Professor Valentin Fuster, M.D., Ph.D., director of the Mount Sinai Heart Center, New York. "Through its combined speed, resolution and sensitivity, Magnetic Particle Imaging technology has great potential for this application, and the latest in-vivo imaging results represent a major breakthrough."
"We are the first in the world to demonstrate that Magnetic Particle Imaging can be used to produce real-time in-vivo images that accurately capture cardiovascular activity," says Henk van Houten, senior vice president of Philips Research and head of the Healthcare research program. "By adding important functional information to the anatomical data obtained from existing modalities such as CT and MR, Philips' MPI technology has the potential to significantly help in the diagnosis and treatment planning of major diseases such as atherosclerosis and congenital heart defects."
Philips' Magnetic Particle Imaging uses the magnetic properties of injected iron-oxide nanoparticles to measure the nanoparticle concentration in the blood. Because the human body contains no naturally occurring magnetic materials visible to MPI, there is no background signal. After injection, the nanoparticles therefore appear as bright signals in the images, from which nanoparticle concentrations can be calculated. By combining high spatial resolution with short image acquisition times (as short as 1/50th of a second), Magnetic Particle Imaging can capture dynamic concentration changes as the nanoparticles are swept along by the blood stream. This could ultimately allow MPI scanners to perform a wide range of functional cardiovascular measurements in a single scan. These could include measurements of coronary blood supply, myocardial perfusion, and the heart's ejection fraction, wall motion and flow speeds.
The results obtained from Philips' experimental MPI scanner mark an important step towards the development of a whole-body system for use on humans. Some of the technical challenges in scaling up the system relate to the magnetic field generation required for human applications. Others lie in the measurement and processing of the extremely weak signal emitted by the nanoparticles. Signal measurement and processing are areas where Philips has a great deal of proven expertise and experience that it is currently applying to the task.
The scientific article "Three-dimensional real-time in vivo magnetic particle imaging" published in issue 54 of Physics in Medicine and Biology (2009) can be downloaded from http://stacks.iop.org/0031-9155/54/L1.
Related news articles:
- Philips Healthcare's Profile
About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified Health and Well-being company, focused on improving people's lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 121,000 employees in more than 60 countries worldwide. With sales of EUR 26 billion in 2008, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.